XML 10 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 11, 2025
Jun. 30, 2024
Cover [Abstract]      
Amendment Flag false    
Document Type 10-K    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000730272    
Current Fiscal Year End Date --12-31    
Document Period End Date Dec. 31, 2024    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Securities Act File Number 000-14656    
Entity Registrant Name REPLIGEN CORP    
Entity Filer Category Large Accelerated Filer    
Trading Symbol RGEN    
Title of 12(b) Security Common Stock    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-2729386    
Entity Address, Address Line One 41 Seyon Street, Bldg. 1, Suite 100    
Entity Address, City or Town Waltham    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02453    
City Area Code 781    
Entity Shell Company false    
Smaller reporting company false    
Emerging growth company false    
Local Phone Number 250-0111    
Document Annual Report true    
Document Transition Report false    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer Yes    
Entity Public Float     $ 5,979,282,111
Entity Common Stock, Shares Outstanding   56,148,556  
ICFR Auditor Attestation Flag true    
Documents Incorporated by Reference

Documents Incorporated By Reference

The registrant intends to file a proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2024. Portions of such proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.

   
Auditor Firm Id 42    
Auditor Firm Name Ernst & Young LLP    
Auditor Firm Location Boston, Massachusetts, United States    
Document Financial Statement Error Correction [Flag] true    
Document Financial Statement Restatement Recovery Analysis [Flag] true    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Repligen Corporation (the Company) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 13, 2025 expressed an adverse opinion thereon.